What Is the sNfL Test for ATTRv V30M Amyloidosis?

The sNfL (serum neurofilament light chain) test is a blood test that measures ongoing nerve damage in people with ATTRv V30M amyloidosis ^[1]. Neurofilament light chain is a structural protein that acts like the internal scaffolding of your nerve cells (axons) ^[2]. When these nerves are damaged by the buildup of misfolded transthyretin (TTR) amyloid proteins, the nerve cells break open and leak sNfL into your bloodstream ^[3][2]. By measuring the amount of sNfL in your blood, your care team can detect active nerve damage in real-time ^[4].

While the test itself only requires a standard blood draw, analyzing sNfL is highly specialized. It is typically ordered through advanced amyloidosis centers or specific commercial neurology laboratories rather than a standard local clinic ^[1].

An Early Warning System for Nerve Damage

For people with the V30M mutation, managing the disease often involves years of careful monitoring before any symptoms appear. The sNfL test serves as a powerful early warning system during this period. Research shows that sNfL levels begin to rise significantly before you ever feel clinical symptoms like numbness, tingling, or weakness, and even before nerve conduction tests show definitive damage ^[1][5].

Doctors use specific thresholds and scoring systems, such as Z-scores, to interpret your results ^[5]. Because sNfL levels naturally increase as we age, a Z-score compares your sNfL level against healthy individuals of your exact age and body size to determine if your level is truly elevated ^[5][6]. This early detection is critical because it helps your doctor pinpoint the exact moment when the disease transitions from silent to active ^[7]. Catching this transition early allows you to start treatment as soon as possible, preserving your nerve function. During this monitoring phase, doctors generally check these levels every 6 to 12 months ^[8].

Monitoring Your Treatment’s Success

Once you are diagnosed with active ATTRv amyloidosis and begin treatment, the sNfL test becomes a vital tool for tracking how well your therapy is working ^[8].

Treatments like TTR silencers (such as patisiran, vutrisiran, or eplontersen) and TTR stabilizers (such as tafamidis) are designed to halt the production or misfolding of the TTR protein ^[9][10]. However, evaluating if these drugs are successfully protecting your nerves based solely on how you feel can be difficult, as nerve healing is a very slow process.

The sNfL blood test provides a much clearer, more immediate picture:

• If your treatment is working: Your sNfL levels will typically drop or remain stable, indicating that the drug is successfully halting further nerve injury ^[11][9].
• If your levels rise: An increasing sNfL level suggests that nerve damage is continuing. This objective data helps your doctor decide if a therapy change is needed, such as switching from a stabilizer to a silencer ^[12][2].

Understanding Fluctuations and Limitations

It is crucial to know that sNfL is a general marker for nerve damage, not exclusive to amyloidosis ^[13]. Your sNfL levels can also rise due to normal aging, a sports concussion, a pinched nerve, or other unrelated neurological conditions ^[3][4]. A minor fluctuation does not automatically mean your amyloidosis is progressing, which is why doctors always evaluate sNfL alongside your physical symptoms and a full clinical assessment.

While the sNfL test is a highly sensitive and convenient tracking tool, it is not a complete replacement for traditional diagnostics. Instead, it is meant to complement foundational tests like skin biopsies or nerve conduction studies, offering a less invasive way to keep a close eye on your nerve health over time ^[8][2].